Roth Capital Downgrades Keryx Biopharmaceuticals (KERX) to Neutral

Roth Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Neutral with a price target of $6.00 (from $11.00) following Q2 results, citing too much hedging.

Analyst Joseph Pantginis commented, "Following 2Q15 results, we believe Auryxia's headwinds are strong at the moment and step to the sidelines awaiting signals of potential strength. While having a profile being "received well" by physicians, the company is 1) increasing the size of the salesforce by 50%, 2) experiencing reimbursement challenges and 3) combatting a lengthy selling cycle."

For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.

Shares of Keryx Biopharmaceuticals closed at $6.27 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
• Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson